Clinical · specific indications. This label summarises the type of data; it is neither a recommendation to use nor a safety rating.
How we read studies and personal accounts ↗Identity
Dronabinol is the international name for the (−)-trans-delta-9-THC stereoisomer. WHO clarifies that the name applies whether plant-derived or synthesised; it does not necessarily denote a different molecule.
Terms associated with this entry: delta-9-THC, Δ9-THC, dronabinol.
Molecule and medicine are different questions
The US label consulted indicates dronabinol for AIDS-associated anorexia with weight loss and chemotherapy-related nausea and vomiting inadequately controlled by conventional treatment. This is US information, not a statement of availability or authorisation in Spain.
Subjective feeling does not measure ability
CDC describes changes in reaction, coordination and perception relevant to driving. It also explains that a THC concentration does not readily determine an individual’s impairment. Feeling accustomed to something and being able to perform a task safely are different questions.
Why naming precisely matters
“Synthetic” may describe how a substance was obtained; it is not enough to identify it. Dronabinol provides a particularly clear example. When reading a report, retain the chemical name, preparation and country, without transferring findings from other cannabinoids to THC or treating every synthetic compound as one clinical category.
What has been studied
Specific medical indications exist for dronabinol; their scope depends on the product and jurisdiction.
Risks and gaps
The label includes psychiatric and cognitive effects, sleepiness, dizziness and possible haemodynamic changes.
Impairment of driving-related skills is a risk, not merely a detail of the experience.
Documented forms
| Pharmaceutical dronabinol capsules | Form documented in the US label; no instructions or access guidance are provided. |
|---|
A molecule and a product are different things. Read about flowers, resins, oils, creams, capsules and vaping.
Experiences
We have not included a verifiable individual account in this review. We do not fill that gap with commercial stories or invented experiences.
Conclusion
A balanced reading keeps limited medical usefulness, intoxication and risks together. An identity profile clarifies what is being discussed; clinical decisions and the legal framework require their own context.
Legal context
Read the Spain note and official sources. Absence from a cited list does not establish that a product is lawful.
Sources
- WHO: clarification of dronabinol identity · Official body
- DailyMed: dronabinol capsule label, May 2026 · Official body
- CDC: Cannabis and Driving · Official body
Source review: 2026-11-02. No external clinical review. Corrections: info@milnubes.com.